Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer4 Nov 2026

971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study

Adil Alaoui¹
Jessica A Catterson²
Michael B Atkins²
Neil J Shah³
Shaked Lev Ari⁴
Olivia Wilkins⁵
Chiranjeev Dash²

5 affiliations

¹4Innovation Center for Biomedical Informatics at Georgetown University, Washington, DC, USA
²Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
³Memorial Sloan Kettering Cancer Center, New York, NY, USA
⁴Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel
⁵MedStar Georgetown University Hospital, Washington, DC, USA

Open at source PDF DOI Cite

Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
Jinyong Kim, Sehhoon Park, Gyeong-Won Lee +16
JTO clinical and research reports21 Aug 2026Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
Prognostic role of the naples prognostic score in advanced gastric cancer treated with immune checkpoint inhibitors: a retrospective multicenter study
Wanfen Tang, Lingfeng Ma, Ziyue Fu +7
Scientific Reports4 Oct 2026Peer-reviewedCC BY 4.0Full textGeneral medicineCrossref
Immune checkpoint inhibitors (ICIs) for second-line retreatment in esophageal cancer progressing after first-line immunotherapy: a single-center retrospective cohort study
Yixin Kang, Youjia Mi, Ce Zhang +4
Journal of thoracic disease10 Sep 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
Lama Alfehaid, Ahmed S. Alanazi, Mansour Alomran +2
Scientific Reports22 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
Risk of de novo immune-related adverse events in patients with cancer and autoimmune disease receiving immune checkpoint inhibitors
Rotana M. Radwan, Grant D. Scheiffele, Wenxi Huang +9
Communications Medicine2 Nov 2026Peer-reviewedCC BY 4.0General medicineNatureCrossref

Cite

BibTeX RIS

BibTeX

@article{alaoui2026impact,
  title = {{971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study}},
  author = {Adil Alaoui and Jessica A Catterson and Michael B Atkins and Neil J Shah and Shaked Lev Ari and Olivia Wilkins and Chiranjeev Dash},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0971},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0971},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 971 The impact of liver metastases on immune-related adverse events in stage IV patients treated with immune-checkpoint inhibitors: a real-world, multicenter, retrospective study
AU  - Adil Alaoui
AU  - Jessica A Catterson
AU  - Michael B Atkins
AU  - Neil J Shah
AU  - Shaked Lev Ari
AU  - Olivia Wilkins
AU  - Chiranjeev Dash
PY  - 2026
DA  - 2026/11/04
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0971
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0971
SN  - 2051-1426
ER  -

Related

Cite